Cleveland Biolabs Inc. (CBLI) and Incuron Announce Results of Studies of CBL0137 in Animal Models of Neuroblastoma  
6/21/2012 9:29:26 AM

BUFFALO, N.Y., June 21, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) and its subsidiary, Incuron, LLC, today announced the results of new studies demonstrating potentially curative effects of CBL0137, in combination with chemotherapy in animal models of neuroblastoma. The results were presented at the Advances in Neuroblastoma Research (ANR) Association 2012 meeting, the world's largest forum on this challenging childhood malignancy, on June 20, 2012, in Toronto, Ontario.